CRM Research Update — June 20, 2026
Updated Thesis
Salesforce, Inc. is a leading enterprise software company specializing in customer relationship management (CRM) and cloud-based applications. The company benefits from a durable competitive moat driven by a dominant global CRM market share in the mid-20% range, stable to slightly widening over the past decade.
The investment grade as of this refresh is A — high business quality. High-tier business, cheap valuation with 45% upside to $220.08 fair value
Key Metrics at a Glance
- Revenue growth: +13.3% year over year
- Net margin: 18.7%
- Forward P/E: 17.5x
- Fair value upside: +45.0% to our estimate of $220
Current price: $151.78
These figures reflect our most recent data pull and are one input into a multi-factor valuation framework.
Our 12–18 Month Outlook
Quality companies held over a multi-year horizon benefit from compounding fundamentals and the patience to ride through short-term volatility. Salesforce, Inc. remains in our covered universe with a high-quality assessment. We update research when material data changes — earnings revisions, management shifts, or regime changes in valuation — not on every price fluctuation.
Long-term accumulation of quality businesses at fair or better prices is the core of the Patient Accumulator approach. Research updates like this one inform whether to add, hold, or wait for a better zone — not whether to react to short-term price moves.
[View full CRM research →](/stocks/CRM)